Emerging oligonucleotide therapeutics for rare neuromuscular diseases

Emerging oligonucleotide therapeutics for rare neuromuscular diseases

Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...

書誌詳細
主要な著者:	Aoki, Y, Wood, MJA
フォーマット:	Journal article
言語:	English
出版事項:	IOS Press 2021

類似資料

Oligonucleotide-based therapies for neuromuscular disease
著者:: Douglas, A, 等
出版事項: (2015)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
著者:: Tsoumpra, MK, 等
出版事項: (2019)

Advances in oligonucleotide drug delivery
著者:: Roberts, TC, 等
出版事項: (2020)

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
著者:: Ashok Verma
出版事項: (2018-01-01)

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
著者:: Gait, M, 等
出版事項: (2018)

Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders
著者:: Ryan Gotesman
出版事項: (2018-11-01)

Development of LNA gapmer oligonucleotide-based therapy for ALS/FTD caused by the C9orf72 repeat expansion
著者:: Sathyaprakash, C, 等
出版事項: (2020)

Antisense oligonucleotides and their applications in rare neurological diseases
著者:: Simon McDowall, 等
出版事項: (2024-09-01)

Oligonucleotides-Based Therapeutics
著者:: Bernard Lebleu
出版事項: (2021-09-01)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
著者:: Marafini I, 等
出版事項: (2020-06-01)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
著者:: Aoki, Y, 等
出版事項: (2011)

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
著者:: Christoph Niemietz, 等
出版事項: (2015-09-01)

Delivery of therapeutic oligonucleotides in nanoscale
著者:: Lei Wu, 等
出版事項: (2022-01-01)

Fine tuning of phosphorothioate inclusion in 2'-O-methyl oligonucleotides contributes to specific cell targeting for splice-switching modulation
著者:: Aoki, Y, 等
出版事項: (2021)

Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides
著者:: Tone, Y, 等
出版事項: (2021)

The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders
著者:: Xiang Li, 等
出版事項: (2023-09-01)

Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency
著者:: Patutina, OA, 等
出版事項: (2020)

Splicing therapy for neuromuscular disease.
著者:: Douglas, A, 等
出版事項: (2013)

The role of chemistry in the success of oligonucleotides as therapeutics
著者:: Pawan Kumar, 等
出版事項: (2022-02-01)

TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases
著者:: Lorena Kumarasinghe, 等
出版事項: (2021-04-01)

Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides.
著者:: Te-Lin Lin, 等
出版事項: (2016-01-01)

Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases
著者:: Xue, K, 等
出版事項: (2020)

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease
著者:: Parekh-Olmedo Hetal, 等
出版事項: (2006-10-01)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
著者:: Davide Di Fusco, 等
出版事項: (2019-03-01)

Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides
著者:: Dysko, A, 等
出版事項: (2022)

Targeting RNA to treat neuromuscular disease.
著者:: Muntoni, F, 等
出版事項: (2011)

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
著者:: Wood, M, 等
出版事項: (2017)

Neuromuscular disorders: therapeutic advances.
著者:: Talbot, K
出版事項: (2007)

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
著者:: Hammond, SM, 等
出版事項: (2021)

Amphiphilic Oligonucleotide Derivatives—Promising Tools for Therapeutics
著者:: Irina A. Bauer, 等
出版事項: (2024-11-01)

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
著者:: Suzan M Hammond, 等
出版事項: (2021-04-01)

Peptide–Oligonucleotide Conjugation: Chemistry and Therapeutic Applications
著者:: Anna L. Malinowska, 等
出版事項: (2024-09-01)

Nonviral delivery systems for antisense oligonucleotide therapeutics
著者:: Si Huang, 等
出版事項: (2022-09-01)

Chemistry of Therapeutic Oligonucleotides That Drives Interactions with Biomolecules
著者:: Chisato Terada, 等
出版事項: (2022-11-01)

Oligonucleotide Therapeutics: From Discovery and Development to Patentability
著者:: Lara Moumné, 等
出版事項: (2022-01-01)

Mesyl phosphoramidate oligonucleotides as potential splice-switching agents: impact of backbone structure on activity and intracellular localization
著者:: Hammond, SM, 等
出版事項: (2021)

Improving translational studies: lessons from rare neuromuscular diseases
著者:: Dominic Wells
出版事項: (2015-10-01)

Therapeutic approaches for Duchenne muscular dystrophy
著者:: Roberts, TC, 等
出版事項: (2023)

Regeneration mechanisms and therapeutic strategies for neuromuscular junctions in aging and diseases
著者:: Masashi Fujitani, 等
出版事項: (2025-01-01)

Editorial: Diagnosis, animal models and therapeutic interventions for neuromuscular diseases
著者:: Muthukumar Karuppasamy, 等
出版事項: (2024-09-01)